PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

• Main Authors: Jayaprakasam Bolleddula (Author), Alice Ke (Author), Hua Yang (Author), Chandra Prakash (Author)
• פורמט: ספר
• יצא לאור: Wiley, 2021-06-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

Abstract Ivosidenib is a potent, targeted, orally active, small‐molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that has been approved in the United States for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are greater than or equal to 75 years of age or...